Resolutions from the Annual General Meeting of Novo Nordisk A/S - Seite 2

• Indemnification of Board members and executives from future liability in addition to any director’s and officer’s liability insurance.
• Amendments to the Remuneration Policy regarding international mobility, claw-back of variable pay, discretion to override the formulaic outcome under incentive programmes, capping of variable pay and incentive targets becoming obsolete.
• Amendments to the Articles of Association regarding an authorisation to hold future General Meetings as fully virtual and partially virtual meetings, the language in documents prepared for General Meetings and an ability to differentiate votes for certain shareholders.
• A proposal from a shareholder on making a plan for changed ownership of the Company was not adopted.

COVID-19 situation

Due to the current COVID-19 pandemic and in order to minimise the spread of the virus, the meeting was held as a fully virtual meeting. Accordingly, shareholders attended by electronic means and had been encouraged to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting.

Composition of the Board of Directors and its committees

After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees.
The Board of Directors, including its committees, is now composed as follows:

• Helge Lund (chair of the Board and chair of the Nomination Committee)
• Jeppe Christiansen (vice chair of the Board and chair of the Remuneration Committee)
• Laurence Debroux (chair of the Audit Committee and member of the Remuneration Committee)
• Andreas Fibig (member of the Audit Committee)
• Sylvie Grégoire (member of the Audit Committee, the Nomination Committee and the Research & Development Committee)
• Mette Bøjer Jensen (employee representative and member of the Nomination Committee)
• Kasim Kutay (member of the Nomination Committee and the Research & Development Committee)
• Anne Marie Kverneland (employee representative and member of the Remuneration Committee)
• Martin Mackay (chair of the Research & Development Committee and member of the Remuneration Committee)
• Henrik Poulsen (member of the Audit Committee)
• Thomas Rantzau (employee representative and member of the Research & Development Committee)
• Stig Strøbæk (employee representative and member of the Audit Committee)

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.